azathioprine has been researched along with Atherogenesis in 3 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Azathioprine treatment was associated with increased CIMT." | 1.35 | Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. ( Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Jung, L; Kimura, Y; Klein-Gitelman, M; Levy, DM; McCurdy, D; Mieszkalski, KL; Punaro, L; Reed, A; Sandborg, C; Schanberg, LE; Sherry, DD; Silver, R; Silverman, E; Singer, NG; Soep, JB; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Merashli, M | 1 |
| Bucci, T | 1 |
| Arcaro, A | 1 |
| Gentile, F | 1 |
| Ames, PRJ | 1 |
| Schanberg, LE | 1 |
| Sandborg, C | 1 |
| Barnhart, HX | 1 |
| Ardoin, SP | 1 |
| Yow, E | 1 |
| Evans, GW | 1 |
| Mieszkalski, KL | 1 |
| Ilowite, NT | 1 |
| Eberhard, A | 1 |
| Levy, DM | 1 |
| Kimura, Y | 1 |
| von Scheven, E | 1 |
| Silverman, E | 1 |
| Bowyer, SL | 1 |
| Punaro, L | 1 |
| Singer, NG | 1 |
| Sherry, DD | 1 |
| McCurdy, D | 1 |
| Klein-Gitelman, M | 1 |
| Wallace, C | 1 |
| Silver, R | 1 |
| Wagner-Weiner, L | 1 |
| Higgins, GC | 1 |
| Brunner, HI | 1 |
| Jung, L | 1 |
| Soep, JB | 1 |
| Reed, A | 1 |
| Moll, R | 1 |
| Hameed, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Test the Safety and Efficacy of Lipitor (Atorvastatin) in Reducing the Progression of Carotid IMT in Early Childhood SLE[NCT00065806] | Phase 3 | 221 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mg/dl (Mean) |
|---|---|
| 1 Atorvastatin | -0.43 |
| 2 Placebo | 0.89 |
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | μmoles/liter (Mean) |
|---|---|
| 1 Atorvastatin | 1.84 |
| 2 Placebo | 1.76 |
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mg/dl (Mean) |
|---|---|
| 1 Atorvastatin | -27.63 |
| 2 Placebo | -1.48 |
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mg/dl (Mean) |
|---|---|
| 1 Atorvastatin | 2.00 |
| 2 Placebo | 6.34 |
For each side and wall of the bifurcation arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right bifurcation near wall max, right bifurcation far wall max, left bifurcation near wall max and left bifurcation far wall max). These summary variables were then averaged to estimate a single mean-max bifurcation CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0033 |
| 2 Placebo | 0.0072 |
For each side, segment and wall, the maximum CIMT over the 4 angles of interrogation was selected to produce 12 summary variables (right common near wall max, right common far wall max, right bifurcation near wall max, right bifurcation far wall max, right internal near wall max, right internal far wall max, left common near wall max, left common far wall max, left bifurcation near wall max, left bifurcation far wall max, left internal near wall max and left internal far wall max). These 12 summary variables were then averaged to estimate a single mean-max CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0037 |
| 2 Placebo | 0.0064 |
For each side and wall of the common carotid arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right common near wall max, right common far wall max, left common near wall max and left common far wall max). These summary variables were then averaged to estimate a single mean-max common CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0006 |
| 2 Placebo | 0.0008 |
For the far wall measurements for each side and segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 6 summary variables (right common far wall max, right bifurcation far wall max, right internal far wall max, left common far wall max, left bifurcation far wall max, and left internal far wall max). These 6 summary variables were then averaged to estimate a single mean-max far wall CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0045 |
| 2 Placebo | 0.0082 |
For each side and wall of the internal carotid arterial segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 4 summary variables (right internal near wall max, right internal far wall max, left internal near wall max and left internal far wall max). These summary variables were then averaged to estimate a single mean-max internal CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0090 |
| 2 Placebo | 0.0144 |
For the near wall measurements for each side and segment, the maximum CIMT over the 4 angles of interrogation was selected to produce 6 summary variables (right common near wall max, right bifurcation near wall max, right internal near wall max, left common near wall max, left bifurcation near wall max, and left internal near wall max). These 6 summary variables were then averaged to estimate a single mean-max near wall CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0024 |
| 2 Placebo | 0.0038 |
For the bifurcation arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right bifurcation near wall mean, right bifurcation far wall mean, left bifurcation near wall mean and left bifurcation far wall mean). These summary variables were then averaged to estimate a single mean-mean bifurcation CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0030 |
| 2 Placebo | 0.0055 |
For each side, segment and wall, mean CIMT values were averaged over the 4 angles of interrogation to produce 12 summary variables (right common near wall mean, right common far wall mean, right bifurcation near wall mean, right bifurcation far wall mean, right internal near wall mean, right internal far wall mean, left common near wall mean, left common far wall mean, left bifurcation near wall mean, left bifurcation far wall mean, left internal near wall mean and left internal far wall mean). These 12 summary variables were then averaged to estimate a single mean-mean CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0033 |
| 2 Placebo | 0.0049 |
For the common carotid arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right common near wall mean, right common far wall mean, left common near wall mean and left common far wall mean). These summary variables were then averaged to estimate a single mean-mean common CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0010 |
| 2 Placebo | 0.0024 |
For the far wall measurements for each side and segment, mean CIMT values were averaged over the 4 angles of interrogation to produce 6 summary variables (right common far wall mean, right bifurcation far wall mean, right internal far wall mean, left common far wall mean, left bifurcation far wall mean and left internal far wall mean). These 6 summary variables were then averaged to estimate a single mean-mean far wall CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0042 |
| 2 Placebo | 0.0064 |
For the internal carotid arterial segment, mean CIMT values were averaged across angles by side and wall to produce 4 summary variables (right internal near wall mean, right internal far wall mean, left internal near wall mean and left internal far wall mean). These summary variables were then averaged to estimate a single mean-mean internal CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0067 |
| 2 Placebo | 0.0082 |
For the near wall measurements for each side and segment, mean CIMT values were averaged over the 4 angles of interrogation to produce 6 summary variables (right common near wall mean, right bifurcation near wall mean, right internal near wall mean, left common near wall mean, left bifurcation wall mean and left internal far wall mean). These 6 summary variables were then averaged to estimate a single mean-mean far wall CIMT for each participant visit. (NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mm (Mean) |
|---|---|
| 1 Atorvastatin | 0.0022 |
| 2 Placebo | 0.0028 |
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | natural log of mg/L (Mean) |
|---|---|
| 1 Atorvastatin | -0.13 |
| 2 Placebo | 0.27 |
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mg/dl (Mean) |
|---|---|
| 1 Atorvastatin | -30.30 |
| 2 Placebo | -0.72 |
(NCT00065806)
Timeframe: Change from baseline to 36 months
| Intervention | mg/dl (Mean) |
|---|---|
| 1 Atorvastatin | -11.04 |
| 2 Placebo | -5.62 |
1 review available for azathioprine and Atherogenesis
| Article | Year |
|---|---|
Subclinical atherosclerosis in Behcet's disease and its inverse relation to azathioprine use: an updated meta-analysis.
Topics: Atherosclerosis; Azathioprine; Behcet Syndrome; Carotid Intima-Media Thickness; Humans; Male; Plaque | 2023 |
2 other studies available for azathioprine and Atherogenesis
| Article | Year |
|---|---|
Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort.
Topics: Adolescent; Atherosclerosis; Azathioprine; Body Mass Index; Carotid Artery, Common; Child; Creatinin | 2009 |
A case of Takayasu arteritis diagnosed at early-phase of disease by conventional CT scanning.
Topics: Adult; Aorta; Aortitis; Atherosclerosis; Azathioprine; Behcet Syndrome; Diagnosis, Differential; Dos | 2012 |